Literature DB >> 1348259

Sulfasalazine-induced fulminant hepatic failure.

G Marinos1, J Riley, D M Painter, G W McCaughan.   

Abstract

We report two cases of massive hepatic necrosis associated with sulfasalazine. Both patients had underlying inflammatory bowel disease. One of the patients had a history of an ill-defined autoimmune disorder (Sjögren's syndrome). Symptoms and signs of a generalized hypersensitivity reaction were present in both patients. One patient died of a subarachnoid hemorrhage while awaiting transplant, the second died 2 weeks after transplant from disseminated aspergillosis. These two cases remind us of one of the potential hazards of sulfasalazine at a time when alternative therapies are now available.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1348259     DOI: 10.1097/00004836-199203000-00012

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  9 in total

1.  Drug-induced hypersensitivity syndrome associated with reactivation of human herpesvirus 6 presenting with severe hepatic injury.

Authors:  Hideaki Miura; Masayuki Nakano; Naoki Yoshimura; Shigehiro Kitamura; Haruki Yamada; Masakazu Takazoe
Journal:  Clin J Gastroenterol       Date:  2008-09-03

Review 2.  Sulfasalazine. A review of its pharmacological properties and therapeutic efficacy in the treatment of rheumatoid arthritis.

Authors:  C P Rains; S Noble; D Faulds
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 3.  Hepatic manifestations of non-steroidal inflammatory bowel disease therapy.

Authors:  Robert Hirten; Keith Sultan; Ashby Thomas; David E Bernstein
Journal:  World J Hepatol       Date:  2015-11-28

4.  Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis.

Authors:  L G Quallich; J Greenson; H M Haftel; R J Fontana
Journal:  BMC Gastroenterol       Date:  2001-08-29       Impact factor: 3.067

Review 5.  Hepatobiliary Manifestations and Complications in Inflammatory Bowel Disease: A Review.

Authors:  Fotios S Fousekis; Vasileios I Theopistos; Konstantinos H Katsanos; Epameinondas V Tsianos; Dimitrios K Christodoulou
Journal:  Gastroenterology Res       Date:  2018-04-07

6.  Successfully treated sulphasalazine-induced fulminant hepatic failure, thrombocytopenia and erythroid hypoplasia with intravenous immunoglobulin.

Authors:  J L Huang; I J Hung; L C Chen; W Y Lee; C Hsueh; K H Hsieh
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 3.650

7.  Effect of Thiol-reducing Agents and Antioxidants on Sulfasalazine-induced Hepatic Injury in Normotermic Recirculating Isolated Perfused Rat Liver.

Authors:  Reza Heidari; Neda Esmailie; Negar Azarpira; Asma Najibi; Hossein Niknahad
Journal:  Toxicol Res       Date:  2016-04-30

8.  Sulfasalazine-induced renal and hepatic injury in rats and the protective role of taurine.

Authors:  Reza Heidari; Maryam Rasti; Babak Shirazi Yeganeh; Hossein Niknahad; Arastoo Saeedi; Asma Najibi
Journal:  Bioimpacts       Date:  2016-03-28

Review 9.  Liver-side of inflammatory bowel diseases: Hepatobiliary and drug-induced disorders.

Authors:  Stefano Mazza; Sara Soro; Maria Chiara Verga; Biagio Elvo; Francesca Ferretti; Fabrizio Cereatti; Andrea Drago; Roberto Grassia
Journal:  World J Hepatol       Date:  2021-12-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.